Discover News Line

(Albany, New York) – 21st Sep 2026 – DelveInsight’s “Polycythemia Vera Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Polycythemia Vera pipeline landscape, covering clinical and nonclinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type, as well as inactive pipeline products.

To know in detail about the Polycythemia Vera pipeline landscape, emerging therapies, and clinical advancements, click here: https://www.delveinsight.com/report-store/polycythemia-vera-pipeline-insight

Some of the Key Facts of the Polycythemia Vera Pipeline Report

• The Polycythemia Vera pipeline includes 20+ key companies developing therapies, with 25+ products spanning Phase III, Phase II, Phase I, preclinical, and discovery stages, along with discontinued and inactive candidates.

• Merck Sharp & Dohme LLC has the most advanced Polycythemia Vera drug candidate in the pipeline, with bomedemstat (MK-3543) currently in Phase III development.

• Bomedemstat is an investigational small molecule, irreversible LSD1 inhibitor being evaluated across a wide range of myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), myelofibrosis (MF), and Polycythemia Vera (PV).

• Flonoltinib, developed by Chengdu Zenitar Biomedical Technology, is an orally bioavailable dual inhibitor of JAK2 and FLT3 currently in Phase II development for Polycythemia Vera.

• PRT12396, developed by Prelude Therapeutics, is an oral, highly selective, allosteric inhibitor of the mutant JAK2V617F protein currently in Phase I development, designed to selectively inhibit mutation-carrying cells while sparing wild-type JAK2 to improve tolerability.

• The JAK2V617F mutation is observed in over 90% of patients with PV, and 50%–60% of primary myelofibrosis and essential thrombocythemia cases, underscoring the centrality of JAK2-targeted approaches in the pipeline.

Polycythemia Vera (PV) Overview

The current understanding of pathophysiology involves increased sensitivity to growth factors due to an abnormal hematopoietic cell clone, with signs and symptoms such as headache, dizziness, claudication, and thrombosis resulting from increased blood viscosity.

Diagnosis has evolved from the older PVSG criteria to the updated WHO 2016 guidelines, requiring either all three major criteria or two major plus one minor criterion, including elevated hemoglobin/hematocrit levels, bone marrow hypercellularity with trilineage proliferation, the presence of JAK2 mutations, and a low serum erythropoietin level as the minor criterion.

There is currently no cure for Polycythemia Vera; treatment goals are aimed at symptom relief and reducing the risk of complications including thrombosis, bleeding, and hematologic transformation, with no current means of preventing transformation into myelofibrosis or acute leukemia/myelodysplastic syndrome.

Discover the latest Polycythemia Vera treatment Market

Polycythemia Vera Emerging Drugs Analysis

• Bomedemstat — Merck Sharp & Dohme LLC

  • Investigational small molecule, irreversible LSD1 inhibitor.

  • Regulates the proliferation of hematopoietic stem cells.

  • Currently in Phase III development for Polycythemia Vera.

• Flonoltinib — Chengdu Zenitar Biomedical Technology Co., Ltd

  • Orally bioavailable dual inhibitor of JAK2 and FLT3.

  • Possesses anti-inflammatory, immunomodulating, and antineoplastic activities.

  • Prevents JAK/STAT and FLT3-mediated signaling.

  • Currently in Phase II development.

• PRT12396 — Prelude Therapeutics

  • Oral, highly selective, allosteric inhibitor of the mutant JAK2V617F protein.

  • Targets the JH2 (pseudokinase) domain.

  • Currently in Phase I development.

Further product details on Givinostat, 9MW3011, SLN-124, INCB000928, GLB-001, AJ1-11095, PXS-5505, and other pipeline candidates are provided in the full report: https://www.delveinsight.com/report-store/polycythemia-vera-pipeline-insight

Polycythemia Vera Drug Therapeutic Assessment

The report provides insights into Polycythemia Vera drugs segregated by the following parameters that define the scope of the assessment:

Polycythemia Vera Clinical Trial Phases

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage products (Phase I)

• Preclinical stage candidates

• Discovery stage candidates

• Discontinued and inactive candidates

Polycythemia Vera Drug Route of Administration

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Polycythemia Vera Product Molecule Type

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Polycythemia Vera Product Type

• Mono

• Combination

• Mono/Combination

Polycythemia Vera Key Companies

• Merck Sharp & Dohme LLC

• Chengdu Zenitar Biomedical Technology Co., Ltd

• Prelude Therapeutics

• Italfarmaco

• Mabwell (Shanghai) Bioscience Co., Ltd.

• Silence Therapeutics plc

• Incyte Corporation

• Hangzhou GluBio Pharmaceutical Co., Ltd.

• Ajax Therapeutics, Inc.

• Syntara

Polycythemia Vera Key Products

• Bomedemstat

• Flonoltinib

• PRT12396

• Givinostat

• 9MW3011

• SLN-124

• INCB000928

• GLB-001

• AJ1-11095

• PXS-5505

Scope of the Polycythemia Vera Pipeline Report

• Geography Covered: Global

• Coverage: 20+ companies and 25+ pipeline drugs across clinical and nonclinical development stages.

• Therapeutic Assessment: Product type, clinical stage, route of administration, and molecule type.

• Additional Coverage: Collaborations, acquisitions and mergers, licensing, designations, and other product-related development activities.

• Pipeline Insights: Discover actionable insights into Polycythemia Vera market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients across the globe. Connect with DelveInsight to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/